Metabolomic Study in Huntington's Disease (METABO-HD)

Not Applicable

• Conditions: Huntington Disease
• Interventions: Biological: blood sample

• Registration Number: NCT03296176
• Lead Sponsor: University Hospital, Angers

Brief Summary

The purpose of this project is to study Huntington's disease by metabolomic approach.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-09
• Study First Submitted: 2017-09-15
• Study First Submitted QC: 2017-09-22
• Study First Posted: 2017-09-28
• Study Start: 2017-10-09
• Last Update Submitted: 2017-10-30
• Last Update Posted: 2017-11-01
• Primary Completion: 2019-09
• Study Completion: 2019-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

For all groups:

• age between 20 and 70 years
• signature of the informed consent
• covered by social security

For presymptomatic group:

• positive genetic test with CAG repeat length ≥ 37 in HTT gene
• Unified Huntington Disease Rating Scale ≤ 5

For symptomatic group:

• positive genetic test with CAG repeat length ≥ 37 in HTT gene
• The Unified Huntington's Disease Rating Scale motor score ≥ 6
• The Total Functional Capacity score ≥ 11

Exclusion Criteria for all groups:

• participation in another therapeutic trial (3 months exclusion period)
• pregnancy and breastfeeding
• persons deprived of their liberty by judicial or administrative decision

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
controls	blood sample	-
presymptomatic	blood sample	-
symptomatic	blood sample	-

Primary Outcome Measures

Name	Time	Method
metabolite mass	at baseline	by chromatography and mass spectrometry

Trial Locations

Locations (1)

CHU Angers; 🇫🇷 Angers, France